Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Biopharmaceutical characterization of the telomerase inhibitor BRACO19.

Taetz S, Baldes C, Mürdter TE, Kleideiter E, Piotrowska K, Bock U, Haltner-Ukomadu E, Mueller J, Huwer H, Schaefer UF, Klotz U, Lehr CM.

Pharm Res. 2006 May;23(5):1031-7. Epub 2006 May 4.

PMID:
16715394
2.

A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.

Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR.

Mol Pharmacol. 2002 May;61(5):1154-62.

PMID:
11961134
3.

BRACO19 analog dimers with improved inhibition of telomerase and hPot 1.

Fu YT, Keppler BR, Soares J, Jarstfer MB.

Bioorg Med Chem. 2009 Mar 1;17(5):2030-7. doi: 10.1016/j.bmc.2009.01.015. Epub 2009 Jan 15.

PMID:
19201200
4.

Decomposition of the telomere-targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential.

Taetz S, Mürdter TE, Zapp J, Boettcher S, Baldes C, Kleideiter E, Piotrowska K, Schaefer UF, Klotz U, Lehr CM.

Int J Pharm. 2008 Jun 5;357(1-2):6-14. doi: 10.1016/j.ijpharm.2008.01.026. Epub 2008 Jan 20.

PMID:
18313869
5.

Human telomerase inhibition by substituted acridine derivatives.

Harrison RJ, Gowan SM, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 1999 Sep 6;9(17):2463-8.

PMID:
10498189
6.
8.
9.

Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors.

Piotrowska K, Kleideiter E, Mürdter TE, Taetz S, Baldes C, Schaefer U, Lehr CM, Klotz U.

Lab Invest. 2005 Dec;85(12):1565-9.

10.

Synthesis and biological evaluation of novel 4,5-bis(dialkylaminoalkyl)-substituted acridines as potent telomeric G-quadruplex ligands.

Laronze-Cochard M, Kim YM, Brassart B, Riou JF, Laronze JY, Sapi J.

Eur J Med Chem. 2009 Oct;44(10):3880-8. doi: 10.1016/j.ejmech.2009.04.021. Epub 2009 Apr 22.

PMID:
19467742
11.
12.
14.

Screening of telomerase inhibitors.

Kleideiter E, Piotrowska K, Klotz U.

Methods Mol Biol. 2007;405:167-80. doi: 10.1007/978-1-60327-070-0_13.

PMID:
18369824
15.

Intestinal transport of bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35.

Yu H, Hu YQ, Ip FC, Zuo Z, Han YF, Ip NY.

Biopharm Drug Dispos. 2011 Apr;32(3):140-50. doi: 10.1002/bdd.745. Epub 2011 Jan 27.

PMID:
21271607
16.

Novel trisubstituted acridines as human telomeric quadruplex binding ligands.

Ungvarsky J, Plsikova J, Janovec L, Koval J, Mikes J, Mikesová L, Harvanova D, Fedorocko P, Kristian P, Kasparkova J, Brabec V, Vojtickova M, Sabolova D, Stramova Z, Rosocha J, Imrich J, Kozurkova M.

Bioorg Chem. 2014 Dec;57:13-29. doi: 10.1016/j.bioorg.2014.07.010. Epub 2014 Aug 10.

PMID:
25171773
17.

Mechanism of acridine-based telomerase inhibition and telomere shortening.

Gunaratnam M, Greciano O, Martins C, Reszka AP, Schultes CM, Morjani H, Riou JF, Neidle S.

Biochem Pharmacol. 2007 Sep 1;74(5):679-89. Epub 2007 Jun 16.

PMID:
17631279
18.

Transport of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) in human respiratory epithelial cells.

Salomon JJ, Endter S, Tachon G, Falson F, Buckley ST, Ehrhardt C.

Eur J Pharm Biopharm. 2012 Jun;81(2):351-9. doi: 10.1016/j.ejpb.2012.03.001. Epub 2012 Mar 8.

PMID:
22426135
19.
20.

Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents.

Martins C, Gunaratnam M, Stuart J, Makwana V, Greciano O, Reszka AP, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2293-8. Epub 2007 Jan 25.

PMID:
17276687

Supplemental Content

Support Center